Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
Previously, EvaluatePharma’s researchers estimated that inclisiran sales could reach $1.529 billion by that time, but analysts would prefer to see that number top at…
Analysts at EvaluatePharma have estimated the drug will be bringing in $2.4 billion in annual sales by 2024.
Its 2022 forecast stands at an awesome $5.2 billion, EvaluatePharma computes, versus a little over $2 billion that it had in 2016 been thought capable of selling.
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
Market researcher Evaluate Pharma put the volume of deals for infectious diseases in the field of infectious diseases last year at $280 million last year.
The market for service providers is expected to grow between 6 and 9% in the next few years, while the pharmaceutical market as a whole should grow by 5.9% annually…
After Saxenda was approved in 2014, analysts forecast that its U.S. sales would top $250 million by 2020, according to a compilation of estimates by market-research firm…
According to EvaluatePharma, drugs designated as orphan drugs will grow by 12.3% per year and top $242 billion in sales by 2024.
By 2024, if approved, EvaluatePharma has said it expects the option to reach peak sales of up to $200 million.
Last year, 78% of the company’s sales came from products that are over 10 years old, analysts at Vantage pointed out in a report released last month.